Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17820825 | 0.82 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL28451183 | 0.81 | MAPT (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL16699574 | 0.80 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL20139837 | 0.79 | CYP2C19 (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL16700910 | 0.78 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL11412055 | 0.77 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL422879 | 0.76 | MAPT (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL1813546 | 0.76 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL1813544 | 0.76 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL21777465 | 0.74 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | CYP3A4 3441/4885CYP2D6 1367/4885CYP2C9 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.